Therapeutic Stratification in Chronic Heart Failure: A 52-Weeks Prospective Study
Ключевые слова:
heart failure, stratification, treatment, IL-6, rehabilitationАннотация
Background: Chronic heart failure (CHF) is a complex syndrome in which systemic inflammation may play a role in its progression and complications. Interleukin-6 (IL-6) is a potential biomarker of inflammation. The aim of this study was to assess the predictive value of baseline IL-6 in CHF.
Materials and methods: This was randomized, double-blind study at the Practical Medical Center of Cardiology, Uzbekistan, between January 2024 and January 2025. We included 165 adult patients with CHF and randomized them to receive standard therapy plus IV iron (n=83) or standard therapy (n=82). Participants had a medical history, NYHA class, transthoracic echocardiography, NT-proBNP, ferritin, transferrin saturation, and serum IL-6 (ELISA) at baseline. The primary outcome was the composite of death and/or hospitalization.
Results: Baseline demographic, clinical, echocardiographic, and laboratory characteristics were comparable between groups. Patients with IL-6≥7 pg/mL had significantly worse event-free survival than those with IL-6<7 pg/mL. By 42 weeks, event-free survival declined to 53% in the high IL-6 group, compared with 77% in the low IL-6 group. Elevated IL-6 was associated with a markedly increased risk of death and/or hospitalization (HR 3.12; 95% CI 1.84-5.29; p<0.0001). Among patients with elevated IL-6, intravenous iron therapy showed a favorable trend toward improved event-free survival (HR=0.54; p≈0.08). NYHA IV status further worsened prognosis in the high IL-6 subgroup.
Conclusions: Baseline IL-6≥7 pg/mL identifies a high-risk inflammatory phenotype in chronic heart failure and may improve prognostic stratification and individualized therapeutic decision-making.
Библиографические ссылки
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356. doi:10.1002/ejhf.1858
Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421-1434. doi:10.1161/CIRCRESAHA.121.318172
Murphy SP, Kakkar R, McCarthy CP, et al. Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(11):1324-1340. doi:10.1016/j.jacc.2020.01.014
Adamo L, Rocha-Resende C, Prabhu SD. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17(5):269-285. doi:10.1038/s41569-019-0315-x
Aimo A, Castiglione V, Borrelli C, et al. Oxidative stress and inflammation in heart failure: focus on interleukin-6. Int J Mol Sci. 2021;22(12):6352. doi:10.3390/ijms22126352
Markousis-Mavrogenis G, Tromp J, Mentz RJ, et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail. 2019;21(8):965-973. doi:10.1002/ejhf.1482
Castiglione V, Aimo A, Panichella G, et al. Interleukin-6 in heart failure with preserved ejection fraction. J Card Fail. 2023;29(12):1643-1654. doi:10.1016/j.cardfail.2023.07.012
Hirota H, Izumimoto T, Matsuoka T, et al. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after coronary angioplasty. Am Heart J. 1995;130(5):1044-1049. doi:10.1016/0002-8703(95)90198-1
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. doi:10.1101/cshperspect.a016295
Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145-156. doi:10.1161/CIRCRESAHA.115.306656
Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102(25):3060-3067. doi:10.1161/01.CIR.102.25.3060
Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31(2):391-398. doi:10.1016/S0735-1097(97)00508-2
Orús J, Roig E, Perez-Villa F, et al. Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant. 2000;19(5):439-446. doi:10.1016/S1053-2498(99)00155-6
Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium; Swerdlow DI, Holmes MV, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9812):1214-1224. doi:10.1016/S0140-6736(11)61914-7
Harrell FE Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. 2nd ed. Springer; 2015.
Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358(20):2148-2159. doi:10.1056/NEJMra0800239